DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
4th Joint Meeting of the
National Center for Advancing Translational Sciences Advisory Council
and Cures Acceleration Network Review Board
September 16, 2013
8:30 a.m. - 5:00 p.m.
Building 31C, 6th Floor, Conference Room 6
Bethesda, Maryland 20892

FUTURE COUNCIL and CAN BOARD MEETINGS

<table>
<thead>
<tr>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAN Board only (by phone)</td>
<td>January 16</td>
</tr>
<tr>
<td>December 12</td>
<td>May 16</td>
</tr>
<tr>
<td></td>
<td>September 19</td>
</tr>
</tbody>
</table>

Agenda – OPEN SESSION
Open Session of the meeting will be webcast. To view, please go to: http://videocast.nih.gov/summary.asp?live=13126

8:30 - 8:50 a.m. Call to Order, Open Session
Christopher P. Austin, M.D. Freda Lewis-Hall, M.D.
Director, NCATS Chief Medical Officer, Pfizer
Chairperson - Advisory Council Chairperson - CAN Review Board

8:50 - 9:00 a.m. Approval of Minutes of 3rd Joint Meeting
Confirmation of Dates for Future NCATS Advisory Council/CAN Review Board Meetings
Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council

9:00 - 9:45 a.m. NCATS Director’s Report
Christopher P. Austin, M.D., Director, NCATS
Discussion
9:45 - 10:00 a.m.  Initiative to Enhance Reproducibility and Transparency of Research Findings
Christopher P. Austin, M.D., Director, NCATS
Discussion

10:00 - 10:30 a.m.  BREAK

10:30 a.m. - 12:30 p.m.  IOM Report on CTSAs (1 hour)
Alan I. Leshner, Ph.D., Chief Executive Officer, American Association for the Advancement of Science
Sharon F. Terry, M.A., President and Chief Executive Officer, Genetic Alliance
Discussion (1 hour)

12:30 - 1:30 p.m.  LUNCH

1:30 - 2:00 p.m.  CAN Review Board Agenda: Other Transaction Authority
Lili M. Portilla, M.P.A., Acting Director, Office of Policy, Communications & Strategic Alliances

2:00 - 2:30 p.m.  Council Subcommittees
• Patient Engagement
  o Margaret A. Anderson, M.A. and Myrl Weinberg, M.A.
• Partnerships with Pharmaceutical and Biotechnology Companies and Venture Capital Firms
  o Freda Lewis-Hall, M.D. and Ankit A. Mahadevia, M.D., M.B.A.
• Medical Technologies (Devices and Diagnostics)
  o Frank L. Douglas, Ph.D., M.D. and Paul G. Yock, M.D.
Discussion

2:30 p.m.  Adjourn, Open Session

2:45 p.m. - 5:00 p.m.  Closed Session
This portion of the meeting is closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

**Review of Conflict of Interest, Confidentiality, and Council Procedures**

Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council

**Council Consideration of Pending Applications**

Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council